Connect with us: 1-844-737-2223

Monday through Friday, 8:30 am to 8:30 pm ET

 
 

comprehensive
coverage support.

 

Your patient’s prescription may be more affordable than you expect, thanks to comprehensive coverage and financial assistance options when enrolled in Acadia Connect™.

 
 
 

Acadia Connect patient eligibility and terms and conditions apply.

†  Around 20% of patients may pay more than $10 for their prescription. As reported by four specialty pharmacy arganizations; Q1 2020 data.

‡  Managed Markets Insight & Technology. Formulary Lookup website. https://formularylookup.com. Accessed August 4, 2020.

 
 
 

Please see Indication and Important Safety Information, including Boxed WARNING, below.

Acadia Connect patient eligibility and terms and conditions apply.

†  Around 20% of patients may pay more than $10 for their prescription. As reported by four specialty pharmacy arganizations; Q1 2020 data.

‡  Managed Markets Insight & Technology. Formulary Lookup website https://formularylookup.com. Accessed August 4, 2020.

 
 

coverage options
regardless of insurance.

 
 

For patients with government insurance (such as Medicare, Medicaid, and other government programs), Acadia Connect may be able to provide information about financial resources that may help your patient.

Patients with commercial insurance that covers their prescription with a co-pay or co-insurance may be eligible to get their medication for $0, regardless of income.

*Acadia Connect patient eligibility and terms and conditions apply.

If patients do not have insurance or their insurance does not cover their prescription, they may be eligible to receive their medication for $0 through the Acadia Connect Patient Assistance Program.

 
 
 
 
 
 

start your patients with a free 14-day supply.

 

Your patients can start their medication with a free 14-day supply when they are enrolled in Acadia Connect. A second free 14-day supply can be provided if extra time is needed prior to authorization. Appropriate patients must be enrolled in Acadia Connect to be eligible for the free 14-day supply of their medication.*

 
 
START ENROLLMENT

* Appropriate patients must be enrolled in Acadia Connect to be eligible for the free 14-day supply. Acadia Connect patient eligibility and terms and conditions apply.

 
 
 
Important Safety Information and Indication for NUPLAZID® (pimavanserin)


WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
  • NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.
  • Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.
  • Warnings and Precautions: QT Interval Prolongation
    • NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics.
    • NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.
  • Adverse Reactions: The common adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).
  • Drug Interactions:
    • Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.
    • Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.
 

Indication

NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

Dosage and Administration

Recommended dose: 34 mg capsule taken orally once daily, without titration.

NUPLAZID is available as 34 mg capsules and 10 mg tablets.

Please read the full Prescribing Information, including Boxed WARNING.

NUPLAZID is a registered trademark of Acadia Pharmaceuticals Inc.